Dublin, Aug. 11, 2022 (GLOBE NEWSWIRE) -- The "Europe Idiopathic Pulmonary Fibrosis Market Size, Share & Industry Trends Analysis Report By Drug Type, By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online Providers, By Country and Growth Forecast, 2021-2027" report has been added to ResearchAndMarkets.com's offering.
The Europe Idiopathic Pulmonary Fibrosis Market is expected to witness market growth of 6.1% CAGR during the forecast period (2021-2027).
Factors such as shifting lifestyle patterns, rising nicotine product usage, and growing health awareness among the general public about efficient IPF management measures are directly proportional to the growth of the overall industry. In addition to pharmacological treatments, IPF patients get a variety of non-pharmacological treatments.
Lung transplants, mechanical ventilation, oxygen therapy, and pulmonary rehabilitation are the most common non-pharmacological treatments. In general, the treatment strategy for IPF is mostly determined by the patient's symptoms, illness stage, and overall health.
Incidence and death rates is expected to rise, and the prevalence of the disease is projected to climb as the population ages. In addition, occupational and environmental exposures, gastric reflux, and hereditary factors are all potential risk factors. Moreover, progressive fibrosis with loss of normal lung tissue results in restricted gas exchange, decreased ventilation, respiratory discomfort and exercise limitation, poor quality of life, and eventually death.
In industrialized countries such as the United Kingdom, the elderly population is growing, and those over the age of 60 are more susceptible to lung diseases. In Western European countries, a large proportion of elderly persons are admitted to hospitals due to respiratory difficulties. In addition, to obtain important clinical proof for their treatments, market companies are forming partnerships with major organizations such as the National Institutes of Health.
According to the European Pulmonary Fibrosis Patient Charter, around 80,000 to 111,000 persons in Europe suffer from IPF, with 30,000 to 35,000 patients diagnosed each year. According to 2017 research by the National Centre for Biotechnology Information (NCBI), 54 percent of patients in Europe do not receive any antifibrotic medication. In 2019, 18.4 percent of EU citizens aged 15 and above reported smoking cigarettes on a daily basis. In fact, just 12.6 percent of EU citizens smoked less than 20 cigarettes per day, whereas 5.9 percent smoked 20 or more cigarettes per day. Such factors reveal the high susceptibility of the regional population towards lung-related diseases.
Scope of the Study
Market Segments Covered in the Report:
By Drug Type
- Pirfenidone
- Nintedanib
By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Providers
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
- GNI Group Ltd.
- Shionogi & Co., Ltd.
- Mission Therapeutics Ltd.
- Galapagos NV
- FibroGen, Inc.
- AstraZeneca PLC
- F. Hoffmann-La Roche Ltd.
- Bristol Myers Squibb Company
- Boehringer Ingelheim International GmbH
- Biogen, Inc.
Key Topics Covered:
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. Europe Idiopathic Pulmonary Fibrosis Market by Drug Type
Chapter 5. Europe Idiopathic Pulmonary Fibrosis Market by Distribution Channel
Chapter 6. Europe Idiopathic Pulmonary Fibrosis Market by Country
Chapter 7. Company Profiles
For more information about this report visit https://www.researchandmarkets.com/r/w677cs
